Steve Ubl, head of the pharmaceutical industry's top trade group, is stepping down from his position at the end of the year. Ubl's tenure included the passage of a law allowing for Medicare to directly negotiate drug prices with manufacturers, a move that has benefited the industry. Since then, the industry has faced multiple challenges, including challenges from the Trump administration, including discredited theories about the safety of vaccines, instability at the FDA, and a desire to lower U.S. drug prices.